Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Top Cited Papers
Open Access
- 1 September 2017
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (9) , 1550-1558
Abstract
Objectives To assess the efficacy and safety of abatacept, a selective T-cell costimulation modulator, in a phase III study in psoriatic arthritis (PsA). Methods This study randomised patients (1:1) with active PsA (~60% with prior exposure to a tumour necrosis factor inhibitor) to blinded weekly subcutaneous abatacept 125 mg (n=213) or placebo (n=211) for 24 weeks, followed by open-label subcutaneous abatacept. Patients without ≥20% improvement in joint counts at week 16 were switched to open-label abatacept. The primary end point was the proportion of patients with ≥20% improvement in the American College of Rheumatology (ACR20) criteria at week 24. Results Abatacept significantly increased ACR20 response versus placebo at week 24 (39.4% vs 22.3%; pConclusions Abatacept treatment of PsA in this phase III study achieved its primary end point, ACR20 response, showed beneficial trends overall in musculoskeletal manifestations and was well tolerated. There was only a modest impact on psoriasis lesions. Trial registration number ClinicalTrials.gov number, NCT01860976 (funded by Bristol-Myers Squibb).Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 43 references indexed in Scilit:
- Subcutaneous abatacept for the treatment of rheumatoid arthritisRheumatology, 2013
- Colonization by Pneumocystis jirovecii and Its Role in DiseaseClinical Microbiology Reviews, 2012
- Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexateArthritis & Rheumatism, 2011
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals of the Rheumatic Diseases, 2010
- Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factorsAnnals of the Rheumatic Diseases, 2009
- The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trialAnnals of the Rheumatic Diseases, 2009
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rateAnnals of the Rheumatic Diseases, 2009
- Psoriatic arthritis: from pathogenesis to therapyArthritis Research & Therapy, 2009
- Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnnals of the Rheumatic Diseases, 2008
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992